Nucleic acid constructs and methods of use

US2016333403A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2016333403-A1
Application numberUS-201615224253-A
CountryUS
Kind codeA1
Filing dateJul 29, 2016
Priority dateApr 30, 2009
Publication dateNov 17, 2016
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides oligonucleotide constructs, sets of such oligonucleotide constructs, and methods of using such oligonucleotide constructs to provide validated sequences or sets of validated sequences corresponding to desired ROIs. Such validated ROIs and constructs containing these have a wide variety of uses, including in synthetic biology, quantitative nucleic acid analysis, polymorphism and/or mutation screening, and the like.

First claim

Opening claim text (preview).

1 . (canceled) 2 . A method for determining sequences of a set of nucleic acid targets, comprising: (a) tagging each end of each nucleic acid target with an identifier from a set of different identifiers to create a set of tagged constructs, wherein the combination of identifiers on each end of a particular nucleic acid target has a high probability of being unique in its association of the particular nucleic acid target from the set of nucleic acid targets; (b) amplifying the set of tagged constructs; (c) sequencing the amplified set of tagged constructs; and (d) using the identifiers and sequence information from step (c), determining sequence of the nucleic acid targets by generating a consensus sequence among molecules that are identical by descent. 3 . The method of claim 2 , further comprising providing nucleic acid targets isolated from a biological sample. 4 . The method of claim 2 , further comprising attaching amplification sites to the tagged constructs, wherein the attached amplification sites flank the nucleic acid target and identifiers. 5 . The method of claim 4 , wherein the amplifying step (b) comprises performing a universal amplification. 6 . The method of claim 2 , wherein the identifiers comprise a degenerate sequence. 7 . The method of claim 2 , wherein the identifiers are selected from a diverse, pre-defined set of oligonucleotide sequences. 8 . The method of claim 2 , wherein the tagging is performed by ligation. 9 . The method of claim 2 , wherein the amplifying comprises PCR. 10 . The method of claim 2 , wherein the amplifying comprises solid-phase amplification. 11 . The method of claim 2 , wherein the amplifying comprises emulsion PCR. 12 . The method of claim 11 , wherein the emulsion PCR comprises beads. 13 . The method of claim 11 , wherein the emulsion PCR comprises magnetic beads. 14 . The method of claim 2 , wherein the sequencing comprises performing massively parallel next generation sequencing. 15 . The method of claim 14 , wherein the next generation sequencing comprises a one pass sequencing method. 16 . The method of claim 14 , wherein the next generation sequencing comprises paired-end sequencing. 17 . The method of claim 14 , wherein the next generation sequencing comprises a hybridization-based method. 18 . The method of claim 14 , wherein the next generation sequencing comprises a sequencing by synthesis method. 19 . The method of claim 14 , wherein the next generation sequencing comprises a ligation-based method. 20 . The method of claim 2 , further comprising inferring a starting number of nucleic acid targets in the set. 21 . The method of claim 2 , further comprising identifying a mutation in a target nucleic acid if it appears in substantially all of the tagged constructs having an identical descent. 22 . The method of claim 2 , further comprising determining one or more sequences or allelic variants of a nucleic acid target in the set of nucleic acid targets.

Assignees

Inventors

Classifications

  • for detection of mutation or polymorphism · CPC title

  • C12Q1/6869Primary

    Methods for sequencing · CPC title

  • C12Q1/6809Primary

    Methods for determination or identification of nucleic acids involving differential detection · CPC title

  • Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes · CPC title

  • C12Q1/6874Primary

    involving nucleic acid arrays, e.g. sequencing by hybridisation · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2016333403A1 cover?
The present invention provides oligonucleotide constructs, sets of such oligonucleotide constructs, and methods of using such oligonucleotide constructs to provide validated sequences or sets of validated sequences corresponding to desired ROIs. Such validated ROIs and constructs containing these have a wide variety of uses, including in synthetic biology, quantitative nucleic acid analysis, po…
Who is the assignee on this patent?
Prognosys Biosciences Inc
What technology area does this patent fall under?
Primary CPC classification C12Q1/6869. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Nov 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).